First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis.
drugs: musculoskeletal and joint diseases
malignant disease and immunosuppression
Journal
BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291
Informations de publication
Date de publication:
04 Feb 2021
04 Feb 2021
Historique:
entrez:
5
2
2021
pubmed:
6
2
2021
medline:
6
3
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitors have revolutionised cancer treatment; however, immune-related adverse events do occur, with up to 7% developing inflammatory arthritis. Common rheumatoid arthritis therapies such as methotrexate, prednisolone and biologics have been used to treat this arthritis in small, uncontrolled case series with varying success. In this case of personalised medicine, we report the first use of tofacitinib, a small molecular inhibitor of the Janus kinase-signal transducer and activator of transcription pathway, to treat checkpoint inhibitor-related inflammatory arthritis. This resulted in a rapid clinical response and complete, sustained remission of the arthritis with associated marked reduction in synovial molecular and cellular immune response.
Identifiants
pubmed: 33541985
pii: 14/2/e238851
doi: 10.1136/bcr-2020-238851
pmc: PMC7868229
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Piperidines
0
Protein Kinase Inhibitors
0
Pyrimidines
0
tofacitinib
87LA6FU830
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Ann Rheum Dis. 2019 Mar;78(3):350-354
pubmed: 30626658
Arthritis Rheum. 2011 Apr;63(4):923-32
pubmed: 21225682
J Immunol. 2017 Mar 15;198(6):2249-2259
pubmed: 28167631
J Immunol. 2015 Apr 15;194(8):3551-3555
pubmed: 25769925
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Arthritis Rheumatol. 2018 Jun;70(6):855-867
pubmed: 29439292
Ann Rheum Dis. 2020 Mar;79(3):332-338
pubmed: 31540935
Ann Rheum Dis. 2021 Jan;80(1):36-48
pubmed: 32327425
J Immunol. 2005 Dec 1;175(11):7372-9
pubmed: 16301644
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Ann Rheum Dis. 2012 Mar;71(3):440-7
pubmed: 22121136
N Engl J Med. 2012 Aug 9;367(6):495-507
pubmed: 22873530
Ann Rheum Dis. 2017 Jan;76(1):43-50
pubmed: 27307501
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
Ann Rheum Dis. 2017 Dec;76(12):2061-2064
pubmed: 28830882
PLoS One. 2018 Feb 28;13(2):e0192704
pubmed: 29489833
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
Arthritis Rheumatol. 2018 Dec;70(12):1959-1970
pubmed: 29790294
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654